Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Biocartis  /  Biocartis forum geopend

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Biocartis BRU:BCART.BL, BE0974281132

  • 0,290 22 sep 2023
  • 0,000 (0,00%) Dagrange 0,000 - 0,000
  • 0

Biocartis forum geopend

6.454 Posts
Pagina: «« 1 ... 182 183 184 185 186 ... 323 »» | Laatste | Omlaag ↓
  2. DRTVR 29 oktober 2020 21:18
    quote:

    ulyss schreef op 29 oktober 2020 19:43:

    Beste,

    ik wens een klacht in te dienen tegen Biocartis ten gevolge van achterhouden informatie en lekken van informatie naar beperkt publiek.

    Daarom dien ik klacht in tegen achterhouden informatie, lekken van informatie en wens ik xxxx schadevergoeding voor de gelede schade
    Dank je wel om mijn klacht in overweging te nemen
    Met vriendelijke groeten

    Gaan we doen, alvast bedankt.
  5. Flatlander 29 oktober 2020 23:57
    I had to leave the office this morning after my earlier posts. I get back and I see BCART has offered some additional information which seemed to obviously be missing this morning (i.e., information on the $12 million in liquidated damages). I suspect the asset returned to BCART was a license to use the idylla platform. The press releases still smack of being very disingenuous! Breast cancer and the need for treatment may be pushed into the future but COVID will definitely not destroy the market. Coming out of the pandemic there will be tremendous pent up demand and more than likely some lab capacity will be tied up with COVID testing. This makes it an ideal time to try to position the POC IVD test like OncoType Dx. I go back to my earlier hypothesis. EXACT is banking on their new precision oncology business and looking to launch labs in foreign markets. The labs are undoubtedly key to their high sensitivity liquid biopsy testing (so they would need the lab regardless of Oncotype DX breast is launched POC or as a conventional lab test). This liquid biopsy test put a huge dent in the Illumina-Grail merger valuation about a month ago.

    The PR also makes no mention of the OncoType Dx prostate test. The prostate collaboration was announced on Dec 4, 2018 (again without much market reaction). How could a PR be released about the termination of the partnership collaboration without mentioning the other product line for which milestone payments have already been paid out?

    The volume today was 10X higher so it shook out a lot of shareholders with really sketchy misleading information. In the U.S., the class action lawyers would be circling. That doesn't happen in Belgium? Someone asked a few pages ago whether I viewed the sell off as a buying opportunity? I sold about a quarter of my position a week or so ago to balance Novacyt gains, but I'm still long a sizeable position. As I posted in early September, I thought the COVID excuse for shelving OncoType DX Breast collaboration was likely misleading. I held onto shares since I believe that POC Oncology MDx
    and Septicyte should find healthy markets when the products are fully registered. I'm not currently buying more shares for two reasons 1) the US tax loss rules require a 30 day waiting period between selling for a tax loss and buying new shares; and 2) the company needs to restore creditability. They should start by disclosing the status of Oncocyte DX prostate. Todays disclosure states that the collaboration termination will have no impact on potential growth in the US. The OncotypeDx prostate test was targeted at US Urology practices. Does that part of the collaboration survive? Worst PR imaginable!

    FL

  6. [verwijderd] 30 oktober 2020 00:32
    Beside the great technology Biocartis has...

    Can I agree with you Flatlander that knowned inside information on 28/10 was not shared to public, but only some inside partners? Causing a big drop of 10% on 28/10

    That press release on 29/10 before opening markets was with hidden information, while US was sleeping, as you. Biocartis knew about the deal of 12M€. Understanding better the drop of 28/10

    And when FSMA blocked the stock, waiting for a press release, suddenly the full information was shared

    So , it"s not a question of good product, its a question of cheating to small share holders

    What is your opinion please?

    Some of us take action based on that information shared by the company, like me
  7. Flatlander 30 oktober 2020 03:09
    Ulyss

    Not sure I totally agree. I'm in Chicago area but I got up early enough to see the 1st PR and down nearly 20%. To late to sell in my mind since it was already at the March lows. The PR statement struck me as extremely poorly thought out and conveyed to the public. My 1st post of the day was that surely their was some type of liquidated damages clause that would provide BCART with compensation for the agreement cancellation. Yes, I think that was negligent not to mention that consideration in the 1st PR. Whether, anyone can document that BCART provided a inside information to a "select few investors" on Oct 28 is a tough thing to prove. The bar for litigation is much lower in the States, I think they would have drawn droves of attorneys with the poorly worded PR and the down 20%.

    I'm wondering who was buying today? One of the things I originally liked about BCART was that the shareholder base was widely disseminated (no one entity or even small group of investors could control outcomes). Since less than 800,000 shares changed hands, it can't have change much.

    Regards
    FL
  8. Flatlander 30 oktober 2020 04:56
    Ulyss

    I think you may need to tone down the allegation that BCART shared inside information on 10/28. EXACT earnings on 10/27 included an impairment charge for the termination of the Idylla IVD. Here is the footnote:

    "(4) During the third quarter of 2020, the Company began discussions with Biocartis regarding the termination of its agreements related to the development of an in vitro diagnostic version of the Oncotype DX Breast Recurrence Score test. As a result, and in connection with the preparation of the financial statements, the Company recorded a non-cash, pre-tax impairment loss of $200.0 million related to the in-process research and development intangible asset that was initially recorded as part of the combination with Genomic Health."

    The bullet points also read:

    "Intangible asset impairment of $209.7 million was primarily related to a one-time impairment of certain in-process research and development assets related to an in vitro diagnostic version of Oncotype DX"

    investor.exactsciences.com/investor-r...

    FL
  10. [verwijderd] 30 oktober 2020 07:50
    quote:

    Flatlander schreef op 30 oktober 2020 04:56:

    Ulyss

    I think you may need to tone down the allegation that BCART shared inside information on 10/28. EXACT earnings on 10/27 included an impairment charge for the termination of the Idylla IVD. Here is the footnote:

    "(4) During the third quarter of 2020, the Company began discussions with Biocartis regarding the termination of its agreements related to the development of an in vitro diagnostic version of the Oncotype DX Breast Recurrence Score test. As a result, and in connection with the preparation of the financial statements, the Company recorded a non-cash, pre-tax impairment loss of $200.0 million related to the in-process research and development intangible asset that was initially recorded as part of the combination with Genomic Health."

    The bullet points also read:

    "Intangible asset impairment of $209.7 million was primarily related to a one-time impairment of certain in-process research and development assets related to an in vitro diagnostic version of Oncotype DX"

    investor.exactsciences.com/investor-r...

    FL
    on 26 and 27/10 nothing special
    on 28/10 big decrease
    on 29/10 before opening, PR

    So some had already the information on 28/10
  13. DRTVR 30 oktober 2020 08:25
    quote:

    Floris de boskaboter schreef op 30 oktober 2020 08:15:

    @DRTVR: meteen instappen of even de eerste piek en mogelijk verdere drop afwachten?
    Hey, ben zeker niet zo thuis in de materie als sommigen hier, maar is er een reden dat het verder naar beneden zou tuimelen, zoals hier beweerd wordt was dat er de laatste 2 dagen gehandeld is met voorkennis, dus als dat de reden was is er verder geen nieuws geweest dat een verdere daling zou rechtvaardigen, maar nog es, laat u niet alleen leiden door mij.
  14. Bonzai1 30 oktober 2020 08:51
    quote:

    Floris de boskaboter schreef op 30 oktober 2020 08:15:

    @DRTVR: meteen instappen of even de eerste piek en mogelijk verdere drop afwachten?
    Het lijkt me dat je jezelf die vraag vanochtend niet meteen zult moeten stellen. Als ik het goed zie, dan is het aandeel 'suspended' op Euronext. Maw: de handel is stilgezet, meer dan waarschijnlijk met het oogpunt op meer broodnodige duiding bij de communicaties van gisteren en de gevolgen voor de koers en het bedrijf. Ik verwacht maw dat de handel pas hernomen zal worden na een uitvoerig persbericht van/over Biocartis ... hopelijk niet over het feit dat er met voorkennis gecommuniceerd en gehandeld is geweest de laatste twee dagen. Dat zou mogelijk het bedrijf en de koers meer schaden en daar zit ikzelf persoonlijk niet op te wachten. Voor zij die hun stukken in paniek verkocht hebben, begrijp ik uiteraard dat zij het anders zien en verwachten ... time will tell :-)
6.454 Posts
Pagina: «« 1 ... 182 183 184 185 186 ... 323 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!